Background The optimal chemotherapy regimen administered currently with radiation in
patients with stage III non-small cell lung cancer (NSCLC) remains unclear. A multicenter …

OBJECTIVE: To evaluate the activity and safety of concurrent thoracic radiotherapy (TRT)
plus weekly paclitaxel/carboplatin (PC) regimen compared with widely used …

Purpose The optimal chemotherapy regimen to use with radiotherapy in stage III non–small-
cell lung cancer is unknown. Here, we compare the outcome of patents treated within the …

Importance The 2 most common chemotherapy regimens used concurrently with thoracic
radiation for patients with unresectable IIIA and IIIB non–small-cell lung cancer (NSCLC) are …

PURPOSE: There are no published survival data after chemoradiotherapy (chemoRT) in
pathologically documented stage IIIB non–small-cell lung cancer. Studies of radiotherapy …

Background The combination of chemotherapy with thoracic radiotherapy (TRT) compared
with TRT alone has been shown to confer a survival advantage for good performance status …

Purpose Concurrent chemoradiotherapy is standard treatment for patients with inoperable
stage III non–small-cell lung cancer (NSCLC). A phase II study by the Southwest Oncology …

Purpose This phase III trial of concurrent thoracic radiotherapy (TRT) was conducted to
compare third-generation chemotherapy with second-generation chemotherapy in patients …

Purpose To demonstrate the efficacy of docetaxel and cisplatin (DP) chemotherapy with
concurrent thoracic radiotherapy (TRT) for patients with locally advanced non–small-cell …

PURPOSE: Recent studies have suggested the superiority of concurrent chemoradiotherapy
and the efficacy of paclitaxel/carboplatin in advanced non–small-cell lung cancer (NSCLC) …